Outlook Therapeutics
OTLK
17 hedge funds and large institutions have $865K invested in Outlook Therapeutics in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
13% more funds holding
Funds holding: 15 → 17 (+2)
0.07% more ownership
Funds ownership: 0.17% → 0.24% (+0.07%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
39% less capital invested
Capital invested by funds: $1.41M → $865K (-$547K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$453K |
| 2 |
LA
LVW Advisors
Pittsford,
New York
|
+$55.4K |
| 3 |
Renaissance Technologies
New York
|
+$45.9K |
| 4 |
Barclays
London,
United Kingdom
|
+$41K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$32.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
-$59K |
| 2 |
Jane Street
New York
|
-$26K |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$23K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.66K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4.12K |
OTLK Hedge Fund Activity: Q4 2019 in Review
17 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q4 2019, worth a combined $865K — down 39% from $1.41M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new OTLK positions and 6 closed out — a net gain of 2 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $453K. The largest seller was United Capital Financial Advisors, exiting entirely with an estimated $59K sold.
- 17 institutional investors held Outlook Therapeutics (OTLK) as of Q4 2019, up from 15 in Q3 2019.
- Funds reported $865K of Outlook Therapeutics stock for Q4 2019, down 39% quarter-over-quarter.
- 8 funds opened new Outlook Therapeutics positions in Q4 2019 and 6 closed out, a net change of +2 holders.
- The largest Outlook Therapeutics buyer in Q4 2019 was Sabby Management, an estimated $453K added.
- The largest Outlook Therapeutics seller in Q4 2019 was United Capital Financial Advisors, an estimated $59K sold.
Based on aggregated 13F filings for Q4 2019.